Hinge Bio

Hinge Bio, Inc. is a privately held biotechnology company leveraging its robust GEM-DIMER™ platform to develop therapeutics addressing resistance, insufficient efficacy, and side effects in the fields of cancer, inflammatory diseases, and infectious diseases. The GEM-DIMER platform creates multivalent, multispecific antibody therapies that engage their targets in a novel way, significantly enhancing bioactivity and providing unique functionalities. The GEM-DIMER technology was invented by Dr. Daniel Capon, Chief Scientific Officer of Hinge Bio, who previously was the first to clone and express recombinant Factor VIII (Genentech), invented Fc fusion proteins (Genentech), and developed chimeric antigen receptors for T-cell therapy/CAR-T (Cell Genesys).